• Number of serious adverse events [ Time Frame: For the duration of the study ] [ Designated as safety issue: Yes ]
• Number of all adverse events [ Time Frame: For the duration of the study ] [ Designated as safety issue: Yes ]
• Number of all - daytime and nocturnal - hypoglycaemic events [ Time Frame: In the 4 weeks before baseline compared to 4 weeks before interim and final visits ] [ Designated as safety issue: Yes ]
• Weight changes compared to baseline [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]
• HbA1c compared to baseline [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]
• Fasting glucose level control compared to baseline as measured by FBG [ Time Frame: After 16 and 32 weeks of treatment ] [ Designated as safety issue: No ]

This study is conducted in Asia. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using insulin detemir under normal clinical practice conditions in the Gulf countries

Inclusion Criteria:

• After the physician decision has been made to use insulin detemir therapy, any subject with Type 2 diabetes is eligible for the study, including newly-diagnosed subjects who have never received insulin or an insulin analogue before. The selection of the subjects will be at the discretion of the individual physician

Exclusion Criteria:

• Subjects who are unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for the final visit;
• Subjects currently being treated with insulin detemir;
• Subjects who previously enrolled in this study or studies related to NovoMix 30;
• Subjects with a hypersensitivity to insulin detemir or to any of the excipients;
• Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 8 months.